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Abstract
Background: The clinical spectrum of Staphylococcus aureus infection ranges from asymptomatic nasal carriage to
osteomyelitis, infective endocarditis (IE) and death. In this study, we evaluate potential association between the presence of
specific genes in a collection of prospectively characterized S. aureus clinical isolates and clinical outcome.
Methodology/Principal Findings: Two hundred thirty-nine S. aureus isolates (121 methicillin-resistant S. aureus [MRSA] and
118 methicillin-susceptible S. aureus [MSSA]) were screened by array comparative genomic hybridization (aCGH) to identify
genes implicated in complicated infections. After adjustment for multiple tests, 226 genes were significantly associated with
severity of infection. Of these 226 genes, 185 were not in the SCCmec element. Within the 185 non-SCCmec genes, 171 were
less common and 14 more common in the complicated infection group. Among the 41 genes in the SCCmec element, 37
were more common and 4 were less common in the complicated group. A total of 51 of the 2014 sequences evaluated, 14
non-SCCmec and 37 SCCmec, were identified as genes of interest.
Conclusions/Significance: Of the 171 genes less common in complicated infections, 152 are of unknown function and may
contribute to attenuation of virulence. The 14 non-SCCmec genes more common in complicated infections include
bacteriophage-encoded genes such as regulatory factors and autolysins with potential roles in tissue adhesion or biofilm
formation.
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Introduction
The clinical spectrum of Staphylococcus aureus is diverse, ranging
from asymptomatic colonization to osteoarticular infections,
endocarditis, and death [1,2,3,4,5,6]. Although a growing body
of evidence suggests that bacterial genetic characteristics may be
associated with distinct clinical manifestations of S. aureus
[7,8,9,10,11,12,13], the association between S. aureus genes and
severity of illness is incompletely understood.
Using multi-locus sequence typing (MLST), we previously
demonstrated a significant association between specific clonal
complexes (CC) and severity of infection in S. aureus [9]. Among
371 clinically well-characterized S. aureus from diverse clinical
settings, we showed that CC5 and CC30 were significantly
associated with hematogenous complications of S. aureus such as
endocarditis, septic arthritis, and vertebral osteomyelitis. Isolates
within these CCs were also implicated using staphylococcal
protein A (spa) [14] and staphylococcal cassette chromosome mec
(SCCmec) typing [15]. However, the genetic basis for these
associations is unknown.
The current investigation seeks to evaluate potential associations
between the presence of specific genes and clinical outcome. To do
PLoS ONE | www.plosone.org 1 April 2011 | Volume 6 | Issue 4 | e18673this, we used a novel array comparative genome hybridization
(aCGH) analysis method to identify individual genes in a large
collection of clinically well-characterized S. aureus isolates from a
wide range of infection severity [16]. We hypothesized that the
association between CC5 and CC30 and hematogenous compli-
cations was due to the presence of specific bacterial genes
contained within these clonal backgrounds, and tested this
hypothesis for over 2,000 genes in the genomes of 239 clinical S.
aureus isolates.
Methods
Subject characteristics
This study was approved by the Duke University Medical
Center (DUMC) Institutional Review Board. Written informed
consent was obtained from all participants involved in this study.
At Duke Medical Center, hospitalized adult patients with at least
one blood culture positive for S. aureus were prospectively identified
between September 1994 and October 2003 [17]. Bacterial
bloodstream isolates were cataloged, stored and corresponding
clinical data were prospectively collected [17]. Twelve weeks after
initial positive blood culture, clinical outcomes were prospectively
assessed. Patients were excluded from the investigation for the
following reasons: outpatient status, age ,18 years, polymicrobial
infection, neutropenia (absolute neutrophil count ,1.0610
9/liter),
death before evaluation by the investigators, injection drug use,
surgery within 30 days, or indwelling prostheses. These exclusion
criteria eliminate important non-pathogen characteristics that can
influence the severity of staphylococcal disease.
Next, we used strict definitions to identify three phenotypically
distinct clinical groups which represent a progression from healthy
individuals to those who are severely affected: 1) nasal carriage, 2)
uncomplicated infection, and 3) bacteremia with hematogenous
complications. Nasal carriage isolates were obtained from the
nares of non-infected subjects in two distinct epidemiologic settings
within the DUMC referral area: a) healthy undergraduate students
with no current infection or healthcare contact (community
carriage isolates) and hospitalized or hemodialysis-dependent
subjects with no active infection (healthcare-associated carriage
isolates).
Isolates in the uncomplicated infection group were obtained
from patients with uncomplicated bacteremia or soft tissue
infection. Uncomplicated bacteremia isolates were obtained from
the bloodstream of DUMC patients meeting all of the following
criteria (in addition to the criteria listed above): a) confirmed
intravascular catheter-associated S. aureus bacteremia [17], b)
receipt of #14 days of antibiotics, c) no evidence of metastatic
infection by both clinical evaluation and echocardiogram, and d)
alive without complications 12 weeks after the initial blood culture.
In addition, to ensure that study findings were not attributable to
the single center design, MSSA isolates (n=48) were obtained
from skin and soft tissue infections of anonymous geographically
diverse patients participating in a Phase II clinical trial (Vicuron
Pharmaceuticals). These patients had a culture-confirmed soft-
tissue S. aureus infection with signs of systemic illness, but sterile
blood cultures documented at the time of enrollment.
Isolates from the third group, bacteremia with hematogenous
complications, were from the bloodstream of patients with definite
native aortic or mitral valve IE [18], hematogenous bone and joint
infection, or both. Patients with bone and joint infection had S.
aureus isolated from a vertebral body, intervertebral disk, or joint
space. All patients with bacteremia were followed up 12 weeks
after the initial positive blood culture to confirm that infection
groupings were accurate.
Microarray design
The S. aureus microarrays used for these experiments were
obtained from the Pathogen Functional Genomics Resource
Center (PFGRC) at The Institute for Genomic Research (TIGR,
now the JCVI) (S. aureus version 3 microarrays). The arrays consist
of 10,800 total spots, with 688 empty spots, 1,024 reserved spots
containing Arabidopsis control oligonucleotides and 9,088 spots
representing duplicate spotted oligos (n=4544 70 base oligomers)
of all known open reading frames in S. aureus at the time of array
construction (N315 and Mu50 [18], MSSA476 and MRSA252
[19], COL [20] and MW2 [21]). The 688 empty spots were used
as negative controls to measure the signal values that represent
background in fluorescence.
Determination of microarray probe specificity
Preliminary examination of hybridization probe specificity
suggested that several microarray probes had the potential to
hybridize to multiple targets. To evaluate the hybridization
specificity of the array probes, we used BLAST to determine the
similarity between all individual probe sequences and the open
reading frames in the S. aureus genomes included on the array.
BLAST was completed using a word size of 30 and the alignment
results filtered to require 90% sequence overlap. The e-value and
bit score were recorded for each probe. Since some probes
matched multiple genes within one genome, the total number of
hits with bit scores above 100 was also noted. All genes that had a
significant probe hit were aligned using CLUSTAL and the
resulting set was then collected and Hidden Markov Models [22]
were used to predict function with the Interpro scan program.
Probes representing known pathogenicity islands, virulence factors
and surface proteins were manually identified and where possible,
ordered to identify their relative position in the S. aureus genome.
Identification of the S. aureus core genome and positive
microarray controls
BLAST alignment of microarray probes (using criteria as
described above) was used to identify which of the 4544 probes are
hybridizing to genes shared among sequenced S. aureus genomes
(COL, N315, MW2, Mu50, MRSA252 and MSSA476). Sequenc-
es with a bit score of greater than 100 in all sequenced genomes,
excluding known virulence factors, surface proteins and genes in
pathogenicity islands (PI) were designated as core (Table S1). The
1930 core probes represent 1660 genes. These probes were used as
positive controls for aCGH analysis of the clinical strains. Of the
remaining 2,614 probes, 600 were determined to not be variable
in our sample based upon hybridization to all (or none) of the
arrays (Table S1). Thus 2,014 variable probes remained, including
virulence factors and other factors likely responsible for increased
fitness or virulence. We used this definition of core and variable in
case some of the known virulence factors were variable in our
study population, even though they were not variable in the
existing sequenced strains. We found this was the case and seven
genes were included in our study in this way. These genes are
serine proteases splC (SACOL1867), splD (SA1628) and splF
(SA1627) and also cap5M (SACOL0148), cell wall hydrolase
(SACOL1264), entertoxin homolog (SA1429) and hypothetical
(SA0850).
Selection of strains
A total of 379 isolates (254 MSSA and 125 MRSA) were in our
initial study [9] based on narrow clinical groupings described
above. The CGH analysis was designed to include all of the
MRSA isolates (n=125) and a 50% random sample of the 244
Potential Virulence Genes of S. aureus
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on clinical severity. Four MRSA isolates and 4 MSSA were
excluded during quality control checks. Thus, the final aCGH
sample for this study included 239 isolates (121 MRSA; 118
MSSA).
Preparation of S. aureus genomic DNA
S. aureus isolates were grown overnight at 37uC in 1.5 ml Brain
Heart Infusion (BHI) media. Genomic DNA was extracted from
500 ml of the cultures using the automated Qiagen M48 extractor
and reagents (Qiagen, Valencia, CA), modified by the addition of
lysostaphin (Sigma, St. Louis, MO) to the cell lysis buffer (final
concentration of lysostaphin at 25 mg/ml).
Array Comparative Genome Hybridization (aCGH)
For hybridization, genomic DNA (500 ng) was amplified in
Klenow reaction buffer containing random oligonucleotide
primers (Invitrogen, Carlsbad, CA), high activity Klenow (New
England Biolabs, Ipswich, MA) and dNTP/ddUTP. Amplified
DNA was coupled to cy3 or cy5 and purified on Qiagen columns
(Qiagen, Valencia, CA) prior to hybridization. The arrays were
hybridized, washed and scanned using standard methods [23]. A
study on a set of already sequenced strains demonstrated that
single replicates where calls of presence/absence were made
relative to negative controls showed greater sensitivity and
specificity than a reference design (data not shown). Accordingly,
we developed a hybridization design where each sample was
hybridized once. The groups (control (C), uncomplicated (U), and
complicated/sick (S) were each balanced for dye such that half of
the samples in a particular group were hybridized with cy3 and
half of the samples with cy5 and different clinical groupings
represented on each slide. The control group was considered the
reference and 36 control strains were repeated. The strains to be
repeated were chosen at random from among all control strains.
Quality control on these repeated hybridizations found excellent
agreement. Images were quantified with Imagene v.7. Local
background signals were subtracted from the signal intensity of the
spot. Imagene’s automated spot flagging feature was used to
identify and remove poor quality spots (i.e. those contaminated by
small dust particles). Each slide was checked to ensure that less
than 5% of the slide was affected by imperfections and poor
quality. Spots were determined to be present if they were greater
than 90% of the negative controls. Validation of the aCGH
method is described in Supporting Information File S1.
Associations
As the primary interest is identifying genes contributing to
severe disease, the uncomplicated and control samples were
combined into a single group, ‘not-complicated’, and compared to
the group, ‘complicated infection’ for significance testing. The
presence/absence of a particular probe was compared to this
binary clinical outcome (not complicated vs. complicated) using a
chi-squared test. P-values for this test were computed exactly as
some comparisons had small cells [24]. A false discovery rate
(FDR), of 0.20 was used to control for multiple testing [25,26,27].
This level was chosen to minimize the chance of failing to identify
important loci. Further descriptive comparisons are reported to be
significant at a nominal level of 0.05. All unadjusted p-values are
reported in Table S2.
PCR verification of microarray data
The presence/absence of the 14 genes associated with severity
of illness was verified by PCR amplification of genomic DNA from
the corresponding strains. The primers, which flank the 70-mer
oligonucleotide probes for these genes, are listed in Table S3.
PCRs were said to agree with array results if simple agreement was
greater than 0.60.
Results
We used aCGH to survey 239 clinical S. aureus isolates with the
goal of identifying genes that may contribute to increased
virulence. The genotypic characteristics of the study subjects with
asymptomatic S. aureus nasal carriage, soft tissue infection,
uncomplicated S. aureus bacteremia and complicated S. aureus
bacteremia are listed in Table 1. Six CCs (CC 1, 5, 8, 15, 30, 45)
out of 15 CCs total, were observed in 10 or more subjects in either
the MRSA or MSSA subset in the current study. The S. aureus
microarray used for this aCGH study allows for resolution of
variations such as gene presence or absence as well as genomic
rearrangements [12], but does not allow detection of individual
DNA polymorphisms [11,28]. Data from this study demonstrate:
1) genetic differences within the 239 isolates, including surface
proteins and toxins, 2) genes unique to CC5 and CC30, 3) genes in
the mec element associated with disease severity and 4) non-mec
genes associated with disease severity (see Table S2).
Table 1. Genotypic characteristics of 239 study subjects.
Sick
a Not Sick
b
Characteristic (N=114) (N=125)
Clonal Complex
c
1 4/112 (3.6%) 14/125 (11.2%)
5 40/112 (35.7%) 26/125 (20.8%)
8 8/112 (7.1%) 11/125 (8.8%)
9 4/112 (3.6%) 0
15 2/112 (1.8%) 10/125 (8.0%)
30 39/112 (34.8%) 30/125 (24.0%)
45 8/112 (7.1%) 12/125 (9.6%)
59 1/112 (0.9%) 3/125 (2.4%)
Other
d 6/112 (5.4%) 19/125 (15.2%)
spa type
c
1 3/111 (2.7%) 4/124 (3.2%)
2 29/111 (26.1%) 21/124 (16.9%)
16 24/111 (21.6%) 14/124 (11.3%)
17 1/111 (0.9%) 3/124 (2.4%)
33 4/111 (3.6%) 6/124 (4.8%)
139 0 2/124 (1.6%)
Other
e 50/111 (45.0%) 74/124 (59.7%)
(a)Includes bacteremia with bone and joint infection only (n=52), native valve
endocarditis only (n=55) and both bone and joint infection and native valve
endocarditis (n=7).
(b)Includes healthy subject nasal carriage (n=31), healthcare-associated nasal
carriage hemodialysis-dependent subjects (n=20), (hospitilized subjects with
no history of hemodialysis dependence (n=18), soft tissue infection (n=21)
and uncomplicated bacteremia (n=35).
(c)Clonal complex and spa types previously described (9) are reported here.
(d)12, 25, 72, 78, 97, 121, 395.
(e)3, 7, 12, 14, 15, 18, 21, 23, 29, 35, 37, 42, 43, 45, 47, 62, 65, 93, 97, 122, 131, 141,
151, 152, 155,163, 168, 175, 176, 184, 193, 194, 199, 203, 204, 220, 247, 314, 363,
390, 433, 437, 449, 466, 487, 493, 499, 501, 503, 504, 505, 506, 507, 509, 514, 517,
518, 520, 521, 522, 524, 527, 529, 530, 531, 535, 536, 537, 538, 540, 541, 544, 546,
547, 548, 549, 596, 597, 598, 599, 600, 601, 602.
doi:10.1371/journal.pone.0018673.t001
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complex
Comparative genomic analysis revealed that the oligonucleo-
tides included on the S. aureus microarray contain 1930 probes to
ORFs common in all sequenced genomes at the time, and 2,614
variable probes. The variable component represents strain specific
genes including virulence factors and surface proteins frequently
present among the sequenced genomes. Analysis of our aCGH
data found that 600 of these probes were not variable in our
sample of 239 strains, with 569 always present and 31 always
absent. The frequency among the 5 major CCs in our study was
calculated for each of the remaining 2,014 probes that were
variable in our population.
Within CC5 and CC30 previously associated with clinical
outcome [9], there were 1232 (61%) sequences that differed in
frequency, with 731 (38%) being more frequent in CC30 and 461
(23%) more frequent in CC5 (Table S2). We also compared the
presence/absence of each probe sequence in CC5 with other (non
CC30) clonal complexes and the presence/absence of each
sequence in CC30 with other (non CC5) clonal complexes. We
found 626 (31%) genes more frequently present in CC30 and 249
(12%) genes more frequently present in CC5. There were 98 genes
more present in both CC5 and CC30 compared to other clonal
complexes.
Genes associated with the SCCmec-element (MRSA)
Our initial study demonstrated that MRSA status was
associated with clinical outcome [9]. In order to understand the
relationship between the 2,014 variable genes and the SCCmec
element and MRSA status, we compared the presence/absence of
genes in MRSA and MSSA strains. We found 140 genes
significantly more frequent in MRSA and 1079 genes more
frequent in MSSA (Table S2).
Genes associated with severe infection
From the 2014 variable sequences, the presence/absence of 226
sequences were statistically significantly associated with severity of
infection (Figure 1 and Table S3). Within these 226 sequences,
there were 41 genes known to be part of a SCCmec element.
Among these 41 genes, 37 were present more frequently in the
complicated group. Of the 185 genes not in the SCCmec element,
14 were present more frequently in the complicated group. For
this study we further focused on these 14 non-SCCmec associated
genes which were more common in the complicated group
(Table 2). The relative proportion of these 14 genes in each of the
major clonal complexes in our study is shown in Figure 2.
Verification of microarray findings
The results of the aCGH analysis were verified by PCR
amplification for 13 of the 14 loci described above. Amplification
of PCR primers failed for one gene (SAR1522). For 12 out of the
13 genes (92.3%), the concordance between the array presence/
absence data and the PCR validation was excellent. In
comparison, the concordance of most large-scale array vs. PCR
comparisons [29,30] is ,60%, clearly demonstrating the quality of
our aCGH data. For genes that were PCR validated, the
Figure 1. Disposition of 4544 aCGH probes. This figure illustrates how we arrived at our candidate genes of interest. Of the 2014 sequences and
239 isolates, a total of 226 sequences were statistically significant after multiple comparisons adjustment. Of these 226 sequences, 185 were not and
41 were in the SCCmec element. Most of the 185 non-SCCmec genes-171-were significantly less common in the complicated infection group. The
remaining 14 genes were significantly more common in isolates from the complicated infection group. Among the 41 SCCmec element genes, 37
were significantly more common in the complicated group and 4 were significantly less common in the complicated group. Therefore, a total of 51 of
the 2014 sequences, 14 non-mec associated and 37 mec associated, were identified as genes of interest.
doi:10.1371/journal.pone.0018673.g001
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PCR results rather than the array results (Table 2).
Discussion
The ability of S. aureus to cause severe infections is dependent
upon a large repertoire of virulence factors, often on mobile
genetic elements or MGE (including pathogenicity islands and
bacteriophage) that are transferred horizontally through the S.
aureus community. The virulence capacity of individual isolates is
largely determined by the function and abundance of these
variable virulence factors. In our previous work [9], we
demonstrated that S. aureus CC5 and CC30 are associated with
the presence of hematogenous complications, including endocar-
ditis, septic arthritis and vertebral osteomyelitis. We now
undertake aCGH analysis to examine the association of 2014
variable S. aureus genes with severity of infection in a collection of
239 isolates with the goal of identifying genes that contribute to
virulence. The 239 S. aureus isolates were selected from three
clinical groups in our previous study [9] and included 121 MRSA
and 118 MSSA isolates. Of the 226 genes that were identified as
significantly associated with severity of infection, 51 were more
frequent and 175 less frequent in the complicated infection group
(Table S4).
We acknowledge that as a result of the microarray probe design
being limited to the six genomes available when the microarray
was constructed, our analysis is compromised and will not capture
Table 2. Putative virulence genes associated with complicated infections.
Clinical Outcome
Common Gene
Name Locus Source Strain Sum Hits
a
Array P-value For
Association
b
PCR P-value For
Association
c
P-value After
Adjust for MRSA
d
Simple
Agreement
transposase/integrase VRA0002 Michigan-VRSA 13 0.0008 0.0007 0.5604 0.927*
transposase/integrase SA1483 N315 3 0.0004 ,0.0001 0.0332 0.899*
thymidylate synthase VRA0005 Michigan-VRSA 1 0.0147 0.152 0.6199 0.89*
hypothetical phage
protein
SAS0928 MSSA476 1 0.0127 0.0018 0.2105 0.99*
prophage amidase/cell
wall autolysin
SA0389 COL 2 0.0112 0.0019 0.4321 0.867*
conserved hypothetical
protein
SA0329 COL 1 0.0205 0.1916 0.4568 0.838*
hypothetical phage
protein
SAR1546 MRSA252 2 0.0227 0.0001 0.0261 0.581
hypothetical phage
protein
SAR1502 MRSA252 1 0.0131 0.0019 0.1661 0.768*
prophage amidase/cell
wall autolysin
MW1380 MW2 2 0.0124 0.0029 0.2461 0.853*
phage regulatory protein SAR1522 MRSA252 4 0.002 n.d. n.d. n.d.
hypothetical protein MW1385 MW2 2 0.0022 0.0011 0.1764 0.994*
conserved hypothetical
protein
SA0338 COL 1 0.0085 ,0.0001 0.0132 0.988*
hypothetical protein SA0397 N315 3 0.0049 0.0219 0.4199 0.755*
putative regulatory
protein
SAR1555 MRSA252 1 0.0146 0.0079 0.7332 0.908*
(a)Sum Hits: the number of times this probe hybridized to a part of the sequenced genomes.
(b)P-value for clinical association from aCGH results.
(c)P-value for clinical association from PCR validation.
(d)P-value for gene association with sick outcome after adjusting for MRSA status.
*Value greater than 0.60 indicates PCR results are in simple aggrement with a CGH results.
doi:10.1371/journal.pone.0018673.t002
Figure 2. Distribution of 14 genes associated with complicated
infections across clonal complexes. Proportion of isolates that
have the 14 genes in each clonal complex shown on a color gradient
with 1 being bright red and 0 being bright blue. All 14 genes are more
abundant in CC5 and 30, the clonal complexes previously shown to
exhibit a significant trend toward increasing levels of hematogenous
complications.
doi:10.1371/journal.pone.0018673.g002
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examples, genes encoding numerous heavy metal resistance genes
on the SCCmec type III element as well as genes encoding the
lukSF-PV Panton Valentine Leukotoxin and ACME element from
Community Acquired MRSA (CA-MRSA) will not be identified in
our analysis. However, a significant strength of our study is
identification of the core S. aureus ORFs present in all tested
clinical strains representing fifteen clonal complexes.
To minimize SCCmec as a confounding factor, the 226 variable
genes were segregated into two groups, based on their presence in
the SCCmec element (Figure 1). Of the 51 genes more common in
complicated infection, 37 were carried on SCCmec and 14 were
not carried on SCCmec. None of these 14 genes encode known
virulence factors previously associated with increased virulence
and disease severity. Instead, 11 genes include proteins of
unknown function, regulatory proteins and autolysins carried on
S. aureus bacteriophage. These findings support previous work
demonstrating the contribution of S. aureus bacteriophage to
pathogenesis of infections [31,32,33,34] through genome varia-
tion, mobilization of pathogenicity islands and transmission of
phage encoded virulence factors.
Yet to be resolved is the contribution of prophage to potentiate S.
aureus virulence by influencing its physiology towards growth as a
biofilm, a virulence factor that plays a role in chronic infections,
such as native valve endocarditis and osteomyelitis. Evidence of
bacteriophage release from S. aureus biofilms has been reported [35],
leading to lysis of cells which in turn promotes the persistence and
survival of remaining cells and release of extracellular DNA (eDNA)
required for extracellular polymeric substance (EPS) development
and maturation of biofilms. A second mechanism for cell lysis and
releaseofeDNA required forbiofilmdevelopment involvesautolysis
driven by autolysins and regulated by the cid and lrg loci [36]. These
autolysins are capable of hydrolyzing the amide bond between N-
acetylmuramic acid and L-alanine in bacterial cell-wall peptidogly-
can resulting in cell lysis and release of eDNA. Interestingly, two of
the bacteriophage genes more frequently present in complicated
infections are autolysins carried on bacteriophages Sa2MW
(MW1380) and L54a (SACOL0389) (Table 2). Although, no role
has yet to be assigned to these two putative autolysin genes, their
presence in cases of complicated infection suggests that they may
influence biofilm maturation and disease persistence. An alternative
function for the S. aureus phage encoded autolysins is suggested by
recent work on bacteriophage-encoded autolysins in Streptococcus
mitis, which demonstrated their role in binding to human platelets
through interaction with fibrinogen [37].
Of the remaining 9 genes carried on prophage, three are DNA
binding proteins with potential regulatory functions (SAS0928,
SAR1502 and SAR1555) and six (SACOL0329, SAR1546,
SAR1522, MW1385, SACOL0338 and SA0397) are genes of
unknown function. The function of three remaining genes
(VRA0002, SA1483 and VRA0005) relative to virulence is also not
clear. Association of these genes with increased disease severity may
be a result of their linkage to unidentified genes not on the microarray
and associated with virulence. This study did not start with candidate
genes, and as such uncovered a list of genes for which little is known
about the function. Detailed functional analysis of these and other S.
aureus bacteriophage genes of unknown function will likely lead to a
greater understanding of their role in virulence and enabling
mutation and adaptation of S. aureus to new environments.
The 37 genes that were more frequently present in complicated
infection and carried by SCCmec span the entire length of the type
II SCCmec element, which is found in the majority (97/120; 81%)
of MRSA isolates included in this study. While there is no direct
evidence that SCCmec contributes to S. aureus virulence, recent
work by Queck et. al. [38] has shown the type II SCCmec elements
encode a new phenol soluble modulin (PSM) that alters the
capacity of S. aureus to cause disease. Although the arrays used in
this study do not contain a probe for this PSM, two genes flanking
the PSM encoding region in SCCmec type II, mecI (N315-SA0039)
and xylR (N315-SA0041) are associated with severity of infection,
suggesting that the new PSM may also be a significant component
in our study. However, sequence analysis of this region showed
that the PSM is present in all members of a subset of 69 isolates
from the study group representing all 3 clinical groups and student
controls. Outside of the SCCmec element, there were 140 genes
associated with SCCmec and severity of infection (Table S4). This
is intriguing as it suggests the possibility of co-evolution of genes in
the S. aureus genome with SCCmec and the possible preferential
insertion of SCCmec into specific strains.
An unexpected finding in our study was the identification of 171
genes more frequent in strains isolated in subjects with
uncomplicated infection. These genes (included in Table S4)
include 152 genes of unknown function, some of which may be
involved in attenuation of virulence. Approximately 38% of S.
aureus genes have no assigned function and an additional 10% have
a putative function based on functional domain matches [39].
Their roles as genes that contribute to S. aureus specific functions
such as pathogenicity or host niche adaptation, remains an
unexplored area of this significant bacterial pathogen.
In summary, we have demonstrated a statistical association
between the presence/absence of individual genes and clinical
outcome. Our data strongly supports the concept that differences in
disease potential are rooted in the S. aureus genotype. However, the
use of aCGH in our current study limits the results to identification
of large-scale genomic changes, such as gain or loss of genes,
responsible for phenotypic changes. Additional genotypic factors,
including genomic polymorphisms, novel genes and differential
gene expression, associated with complicated infections, will be
determined by resequencing of representative members of the
SABG collection and global transcriptional analysis from in vitro and
in vivo environments. Correlation of these genomic and transcrip-
tional differences with clinical outcome will contribute significantly
to our understanding of S. aureus virulence.
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